AI Article Synopsis
- Ovarian cancer treatment primarily involves cisplatin-based chemotherapy, but many patients experience recurrent and resistant disease.
- A study evaluated the effectiveness of topotecan in patients with recurrent ovarian cancer or those resistant to cisplatin, using a chemosensitivity assay on 41 tissue samples.
- Results indicated that topotecan was significantly more effective (80.5% sensitivity) compared to cisplatin (51.2% sensitivity), especially in cisplatin-resistant cases where 90% of samples showed sensitivity to topotecan.
- The findings suggest that topotecan could serve as a promising second-line treatment for these patients.
Article Abstract
Background & Objective: The therapeutic principle of ovarian cancer was cytoreductive surgery assisting with chemotherapy. At present, cisplatin-based chemotherapy is the primary way for treatment of ovarian cancer. But most patients with advanced ovarian cancer were easy to recurrent and then become resistance to cisplatin. This study was designed to evaluate the clinical application of topotecan in recurrent ovarian cancer and ovarian cancer resistant to cisplatin.
Methods: An adenosine triphosphate chemosensitivity assay (ATP-CSA) was used to determine the drug sensitivity of 41 tissue specimens of fresh ovarian cancer. Cisplatin and topotecan were used as chemotherapeutic agents [1xPeak Plasma Concentration (PPC)], and then the results were analyzed.
Results: (1) In 41 specimens, the results showed that topotecan was more sensitive (80.5%) than cisplatin (51.2%). (2) In 20 cisplatin-resistance specimens, there were 18 specimens sensitive to topotecan.
Conclusions: Topotecan could be a kind of better second line drug in treating ovarian cancer, particularly when the patient was resistant to cisplatin.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
AMH protects the ovary from doxorubicin by regulating cell fate and the response to DNA damage.
Proc Natl Acad Sci U S A
February 2025
Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Boston, MA 02114.
Anti-Müllerian hormone (AMH) protects the ovarian reserve from chemotherapy, and this effect is most pronounced with Doxorubicin (DOX). However, DOX toxicity and AMH rescue mechanisms in the ovary have remained unclear. Herein, we characterize the consequences of these treatments in ovarian cell types using scRNAseq.
View Article and Find Full Text PDFRole of Leucine-Rich Repeat-Containing G-Protein-Coupled Receptors 4-6 (LGR4-6) in the Ovary and Other Female Reproductive Organs: A Literature Review.
Cell Transplant
January 2025
Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien.
Leucine-rich repeat-containing G-protein-coupled receptors regulate stem cell activity and tissue homeostasis within female reproductive organs, primarily through their interaction with the Wnt/β-catenin signaling pathway. LGR4-6 are increasingly recognized for their roles in organ development, regeneration, and cancer. This review aims to provide a comprehensive overview of the roles of LGR4-6 in female reproductive organs, highlighting their significance in normal physiology and disease states, specifically in the context of ovarian cancer.
View Article and Find Full Text PDFIdentification of a TNIK-CDK9 axis as a targetable strategy for platinum-resistant ovarian cancer.
Mol Cancer Ther
January 2025
University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
Up to 90% of high-grade serous ovarian cancer (HGSC) patients will develop resistance to platinum-based chemotherapy, posing substantial therapeutic challenges due to a lack of universally druggable targets. Leveraging BenevolentAI's AI-driven approach to target discovery, we screened potential AI-predicted therapeutic targets mapped to unapproved tool compounds in patient-derived 3D models. This identified TNIK, which is modulated by NCB-0846, as a novel target for platinum-resistant HGSC.
View Article and Find Full Text PDFLoss of phosphatase and tensin homolog () increases Lysyl oxidase-like 2 () expression enhancing the growth of fallopian tube epithelial cells as three-dimensional spheroids.
Cancer Pathog Ther
January 2025
Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois, Chicago, IL 60607, USA.
Background: High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of all ovarian cancer-related deaths. Multiple studies have suggested that the fallopian tube epithelium (FTE) serves as the cell of origin of HGSOC. Phosphatase and tensin homolog () is a tumor suppressor and its loss is sufficient to induce numerous tumorigenic changes in FTE, including increased migration, formation of multicellular tumor spheroids (MTSs), and ovarian colonization.
View Article and Find Full Text PDFOvarian cancer risk reduction by salpingectomy during non-gynaecological surgery: scoping review.
BJS Open
December 2024
Department of Obstetrics and Gynecology, and Catharina Cancer Institute, Catharina Hospital, Eindhoven, The Netherlands.
Background: Ovarian cancer is the leading cause of death among gynaecological cancers. The identification of the fallopian tube epithelium as the origin of most ovarian cancers introduces a novel prevention strategy by removing the fallopian tubes during an already indicated abdominal surgery for another reason, also known as an opportunistic salpingectomy. This preventive opportunity is evidence based, recommended and established at the time of gynaecologic surgery in many countries worldwide.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!